C. Botella-Garcia

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

M. Beksac, I. Yakoub-Agha, J. Passweg, 2022, Bone Marrow Transplantation.

Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT

M. Labopin, D. Blaise, A. Nagler, 2022, Bone Marrow Transplantation.

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

P. Chevallier, S. Nguyen, A. Berceanu, 2021, Blood.

Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study

P. Chevallier, M. Béné, R. Gressin, 2022, Acta oncologica.

A 16‐month‐long experience of COVID‐19 in allogeneic haematopoietic stem cell transplantation recipients: An SFGM‐TC multicentre cohort study

M. Robin, P. Chevallier, A. Thiébaut, 2023, British journal of haematology.

Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study

M. Robin, P. Chevallier, I. Yakoub-Agha, 2020, American journal of hematology.

Nocardia Infections in Hematopoietic Cell Transplant Recipients: A Multicenter International Retrospective Study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

D. Lebeaux, M. Aljurf, O. Lortholary, 2021 .